Quarterly Activities Report – September 2025
October 21, 2025
Key Highlights: Positive Feedback from FDA Supports Company’s Plans to File an IND in Q4 2025 Wayne State University Collaboration in MRI adds to existing
Press & Media Coverage
Catch up on our latest press coverage
Imagion Biosystems HER2 Breast Cancer Program Update
October 7, 2025
Key Highlights: Manufacturing of the MagSense® HER2 Breast Cancer Imaging Agent for the Phase 2 clinical trial has been completed – major milestone achieved IBX,
Imagion Biosystems EGM Chairman’s Address
September 24, 2025
Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilizing its proprietary MagSense® imaging
Pitt Street Research – “Detecting cancers earlier” with Imagion Biosystems
September 11, 2025
Imagion Biosystems (ASX: IBX) is at a pivotal point of its history, about to take its MagSense technology into Phase 2. Abstract: MagSense is a
Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway
September 9, 2025
Highlights Dr Nina Webster appointed as IBX Non-Executive Director, bringing significant clinical development expertise and corporate experienceto the IBX Board ahead of HER2 Breast cancer
Dr. Nina Webster Joins IBX Board of Directors
September 1, 2025
Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilizing its proprietary MagSense® imaging
Watch our latest media coverage
Recent Press Coverage
14:13
4:13
4:09
4:19
16:09
5:26
7:30
16:30
18:44
3:10
4:41
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.